Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05690503
PHASE2

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Sponsor: New York State Psychiatric Institute

View on ClinicalTrials.gov

Summary

Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-03-20

Completion Date

2025-12-31

Last Updated

2024-07-16

Healthy Volunteers

No

Interventions

DRUG

CI-581a

Medication infusion intravenously over 90 minutes.

DRUG

CI-581b

Medication infusion intravenously over 90 minutes.

Locations (1)

New York State Psychiatric Institute

New York, New York, United States